Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
305.1(c) 311.13(c) 321.5(c) 331.88(c) 324.21(c) Last
7 625 781 10 193 213 12 770 612 12 851 338 17 123 093 Volume
+0.06% +1.98% +3.33% +3.23% -2.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 20 335 M - -
Net income 2021 12 514 M - -
Net cash position 2021 12 947 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Sales 2022 20 811 M - -
Net income 2022 10 589 M - -
Net cash position 2022 25 316 M - -
P/E ratio 2022 13,4x
Yield 2022 -
Capitalization 131 B 131 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,07x
Nbr of Employees 1 300
Free-Float 90,3%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
More about the company
Ratings of Moderna, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MODERNA, INC.
03:56pMODERNA : U.S. administers 407.4 mln doses of COVID-19 vaccines -CDC
RE
03:35pMODERNA : U.S. CDC Says Administered 407,446,961 Doses Of COVID-19 Vaccine As Of Oct 16
RE
10/15Stocks rise on strong earnings reports
RE
10/15MODERNA : Wall St ends up with Goldman; Dow posts biggest weekly rise since June
RE
10/15JOHNSON & JOHNSON : COVID-19 Vaccine Booster Shot Receives FDA Advisory Panel Recommendati..
MT
10/15MODERNA : NIH's Collins Says FDA Wants to Study Moderna Covid Shot in Kids Longer
MT
10/15MODERNA : U.S. administers 406.6 mln doses of COVID-19 vaccines - CDC
RE
10/15FDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
10/15MODERNA : Wall St climbs after week of strong bank results; market set for weekly gains
RE
10/15MODERNA : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different ..
RE
10/15PFIZER : FDA panel endorses booster shot for J&J COVID-19 vaccine
AQ
10/15Equities Climb Midday With Yields After Surprise Retail Sales Gain
MT
10/15MIDDAY REPORT : US Stocks Climb With Yields After Surprise Retail Sales Gain; Bitcoin Tops..
MT
10/15MODERNA : U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ
RE
10/15PFIZER : FDA panel takes up tough questions on J&J COVID-19 boosters
AQ
More news
News in other languages on MODERNA, INC.
10/15Wall Street se retrouve avec Goldman ; le Dow Jones affiche sa plus forte hausse hebdom..
10/15MÄRKTE USA/Wall Street geht mit deutlichen Aufschlägen ins Wochenende
10/15La piqûre de rappel du vaccin COVID-19 de Johnson & Johnson reçoit la recommandation du..
10/15USA : un comité d'experts recommande une dose supplémentaire au vaccin anti-
10/15USA : FDA-Gremium empfiehlt auch Corona-Booster mit Johnson & Johnson
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 2020
The beginning of the move
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 324,21 $
Average target price 299,31 $
Spread / Average Target -7,68%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414
ALNYLAM PHARMACEUTICALS, INC.60.47%24 787